Facio raises €8M in equity financing


Leiden, the Netherlands - November 16, 2018

Facio Therapies announced today that it had successfully completed an equity financing round with proceeds of €8M (approximately A$12.5M; C$12M; US$9M). FSHD Spain and 30 other members of the FSHD community newly invested alongside existing investors, including Facio’s drug discovery partner, Evotec. Facio will use these funds to expand its recently announced in vivoproof of principle… read more

Facio achieves first-ever in vivo proof of principle in FSHD


Leiden, the Netherlands - October 31, 2018

Facio Therapies announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”). The key event in FSHD… read more

Facio selects lead candidates for FSHD drug development


Leiden, the Netherlands - September 11, 2018

Facio Therapies announced today that it has selected several small-molecule compounds as lead candidates for FSHD drug development. Representing a novel mechanism to repress DUX4, these compounds selectively target an enzyme that is active in FSHD-affected muscle cells. The key event in FSHD is the undue production of the DUX4 protein in skeletal muscle. DUX4 sets… read more

Facio broadens portfolio of potential drug development candidates


Leiden, the Netherlands - August 30, 2018

Facio Therapies announced today that it has selected a second series of potential candidates for FSHD drug development. This series encompasses a family of novel small-molecule compounds that repress DUX4 by engaging a molecular target that differs from the target of Facio’s first series of potential drug development candidates. The key event in FSHD is… read more

Facio Board member, Bill Moss AO, speaks with The Australian


Leiden, the Netherlands - June 4, 2018

Facio Therapies announced today that its Board member, Bill Moss AO, was interviewed by the leading Australian newspaper, The Australian. Speaking with The Australian’s Sarah-Jane Tasker, Bill shared his quest to find a cure for FSHD and explained how Facio’s patient-driven, single-focus and capital-efficient model is uniquely geared towards developing a therapy that is not only safe and… read more

Facio’s parent publishes Annual Report 2017


Leiden, the Netherlands - April 24, 2018

Facio Therapies announced today that its parent company, FSHD Unlimited, published its Annual Report for the year 2017 that consists of a Board Report and the audited annual accounts. Facio ended 2017 with the selection of its first series of potential FSHD drug development candidates and with over €3M in cash, which will enable Facio… read more

Facio to present at the Orphan Drugs for Rare Diseases Summit


Leiden, the Netherlands - March 19, 2018

Facio Therapies announced today that its managing director, David Dasberg, will present at the Orphan Drugs for Rare Diseases Summit that will be held in Berlin on March 22-23, 2018. Facio solely focuses on FSHD. The cause of FSHD is undue production of DUX4 in skeletal muscle. DUX4 sets in motion a cascade of biochemical events… read more

Facio names Director, Finance


Leiden, the Netherlands - February 1, 2018

Facio Therapies announced today that Frank Niemöller joined as Director, Finance. Frank brings over 25 years’ experience in finance and operations management in the biotech, medtech, health insurance, and internet sectors. For the last 12 years, Frank Niemöller was chief financial officer and statutory director of Optelec Holding BV, a leader in the development and… read more

Facio selects first series of potential drug development candidates


Leiden, the Netherlands - January 19, 2018

Facio Therapies announced today that it has selected its first series of potential FSHD drug development candidates. This series comprises several families of small-molecule compounds that are associated with a narrowly defined target class. Neither the compound families nor the target class have ever been linked to FSHD in the scientific literature. Undue production of… read more